Nicorandil, a new KATP channel opener, is used in clinical practice for anti-anginal therapy. It exhibits vasodilator properties as does the halogenated anaesthetic isoflurane. We have examined the cardiovascular effects of increasing concentrations of isoflurane after administration of nicorandil in 10 adult beagle dogs anaesthetized with thiopental and whose lungs were ventilated mechanically. During surgery, anaesthesia was maintained with 1.0-1.5% isoflurane. A left thoracotomy was performed and the heart suspended in a pericardial cradle. Monitoring included: ECG; aortic, left ventricular, arterial, central venous and pulmonary artery pressures; cardiac output; coronary flow; and segmental length in the apical region. After surgery, isoflurane anaesthesia was set at an end-tidal concentration of 1.05% (1 MAC) and measurements obtained; these were repeated with 1.4%, 1.75%, 2.1% and 1.05% isoflurane concentrations after appropriate stabilization periods. Nicorandil (100 g kg 91 bolus, 25 g kg 91 min 91 infusion) was begun and a second dose-response study of isoflurane was obtained as before. Blood samples were obtained for measurement of concentrations of nicorandil. Systolic ventricular function was assessed by systolic shortening (%SS) and preload recruitable stroke work (PRSW). Increasing isoflurane concentration produced decreases in heart rate, systolic pressure, cardiac output, %SS and PRSW. Nicorandil produced a slight decrease in systolic arterial pressure (10 and 15 mm Hg after 1.05% and 2.05% isoflurane) and a slight increase in heart rate (10 and 5 beat min 91 after 1.05% and 2.05% isoflurane). Preload, assessed by end-diastolic length, decreased. Coronary blood flow increased with infusion of nicorandil. Left ventricular function was not affected by infusion of nicorandil. We conclude that nicorandil has only minor vaso/venodilatory effects in the presence of isoflurane. Ventricular function was not altered by infusion of nicorandil. (Br.
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Nicorandil, an ATP-sensitive potassium (K ATP ) channel opener, is a potent vasodilator whose anti-anginal and anti-ischaemic actions can be attributed to its profound vasodilatory effects on the arterial and venous circulation 1 and to a specific cardioprotective effect via opening of the K ATP channel during ischaemia. 2 This vasodilator has little effect on cardiac contractility, produces increases in coronary blood flow and decreases in systemic arterial pressure. 2 The mechanism of action is two-fold: a nitrate-like effect mediated by an increase in cyclic GMP and a selective increase in K ; conductance of smooth muscle cell membrane.
1 Nicorandil effectively unloads the heart, producing a decrease in peripheral resistance and an increase in venous capacitance. 3 4 Isoflurane, a halogenated anaesthetic agent, depresses myocardial contractility 5 and acts as a dose-related vasodilator. 6 Increasing the concentration of isoflurane produces dose-related decreases in systemic pressure, heart rate and contractility. 5 The effects of isoflurane have been attributed in part to alterations in trans-sarcolemmal calcium flux. 7 Moreover, vasodilatory 8 9 and cardioprotective [10] [11] [12] properties of isoflurane seem to be mediated in part via opening of the K ATP channel. With the possibility of an increase in the number of anginal patients receiving nicorandil presenting for surgery, we have examined the cardiovascular effects of nicorandil on the response to graded concentrations of isoflurane on haemodynamic and ventricular variables to determine if there is an additive action of isoflurane and nicorandil.
Materials and methods
The study conformed to the UK Animals Act (Scientific Procedures, 1986). We studied 10 adult beagle dogs of both sexes (weight 10-12 kg), premedicated with morphine 1.0 mg kg 91 i.m. and anaesthetized with thiopental 15 mg kg 91 i.v. After tracheal intubation the animals were placed on their right side and underwent mechanical ventilation (40% oxygen in nitrogen). Anaesthesia was maintained with 1.0-1.5% isoflurane. Inspiratory and end-tidal gas concentrations were measured continuously (gas analyser M1025A, Hewlett Packard, Bracknell, UK) and mechanical ventilation adjusted to maintain end-tidal carbon dioxide concentration at 4.5-5.5%. Mid-oesophageal temperature was maintained at 36-37ЊC using a Servo-controlled heating element incorporated into the operating table. Hetastarch 5 ml kg 91 h 91 was infused continually via an i.v. cannula inserted into the inferior vena cava via a vein in the left hind leg. Left thoracotomy was performed, the fifth and sixth ribs excised, and the heart suspended in a pericardial cradle.
Monitoring included limb lead II of the ECG (subcutaneous needle electrodes); a piece of thin rubber tubing around the inferior vena cava distal to the right atrium for caval occlusion; a 7-French gauge pulmonary artery catheter (Swan-Ganz, American Edwards Laboratories, Anasco, Puerto Rico) inserted via the left jugular vein for measurement of central venous pressure, pulmonary artery pressure and cardiac output; and a 8-French gauge rigid fluid-filled cannula in the descending aorta, inserted via the femoral artery and connected to a pressure transducer (Druck, Druck Ltd, Groby, Leicester, UK) for measurement of systemic arterial pressure during surgery. Two micromanometertipped 8-French gauge catheters (Millar, Houston, TX, USA) were used to measure pressure in the ascending aorta (inserted via the left common carotid artery to within 1 cm of the aortic valve) and in the left ventricle (inserted via a stab wound in the apical dimple); a Doppler flow probe (Triton, San Diego, CA, USA) was placed around the left anterior descending coronary artery (LAD); and a pair of piezoelectric crystals (Triton, San Diego, CA, USA, 2 mm in diameter, 5 MHz) for ultrasonic measurement of segmental length were implanted parallel to the minor axis, in the apical region, in an area depending on the LAD blood supply. These were implanted in the subendocardium approximately 10 mm apart through epicardial stab wounds.
After surgery isoflurane was adjusted to 1.05% (1 MAC) end-tidal concentration. After a 30-min stabilization period, the first measurements were obtained. End-tidal isoflurane concentration was increased to 1.4% (1.3 MAC) and the preparation allowed to stabilize for 20 min. Further measurements were recorded. Thereafter measurements were obtained at 1.75% (1.7 MAC) and 2.1% (2 MAC) isoflurane, allowing the preparation to stabilize at each stage. The isoflurane concentration was then decreased to 1.05% (1 MAC) and the preparation allowed to stabilize for 30 min, with measurements obtained at the end of this period. Nicorandil (100 g kg 91 bolus, 25 g kg 91 min 91 infusion) (Merck KGaA, Darmstadt, Germany, dissolved in NaCl 0.9% (w/v)) was infused into the vein in the hind leg and measurements obtained after 30 min; thereafter isoflurane was increased in a stepwise manner as before, with measurements obtained at each stage.
Blood samples were obtained just before (T0), 30 min after infusion of nicorandil (T1) and at the end of the study (T2) for measurement of plasma concentrations of nicorandil.
All sets of measurements consisted of: (1) cardiac output measured in triplicate using thermodilution (COM-2 Baxter, Santa Ana, USA), (2) steady state haemodynamic variables, and (3) recordings during caval occlusion (obtained by pulling the rubber tubing around the inferior vena cava for 8-10 s). Steady state haemodynamic variables were recorded for 5 s and caval occlusion data for 15 s. All measurements were made during expiratory apnoea.
MEASUREMENT OF NICORANDIL CONCENTRATIONS
Plasma concentrations of nicorandil were measured chromatographically. Blood samples were collected in test tubes containing lithium heparinate. Alkalinized plasma (2 ml), spiked with nicotinoylamidopropyl nitrate 2.5 ng ml 91 (SG 89, Merck KGaA, Darmstadt, Germany) as an internal standard, was ECG, pressures (aortic, left ventricular, arterial), coronary flow and regional dimension signals were converted using an analogue-digital converter (AT-MIO-16, National Instruments Corporation, Austin, TX, USA) and displayed continuously on an IBM AT personal computer using the real-time mode of software designed in this department. Data were sampled at a frequency of 500 Hz and stored on hard disc.
DATA ANALYSIS
Data analysis was performed on an IBM AT personal computer using the play-back mode of the above software. Peak positive left ventricular pressure dP/dt was obtained by electronic differentiation of the LV pressure signal. End-diastole was defined as the first upward (positive) deflection of the left ventricular dP/dt signal. End-systole was defined at peak negative dP/dt.
All length measurements were normalized to an initial value of end-diastolic length of 10 mm at control. The following definitions were used to quantify regional wall motion: EDL:end-diastolic length; ESL:end-systolic length. Systolic shortening (%SS) was defined as follows:
%SS=(EDL ESL)/EDL 100 − × Segmental stroke work (SW) was calculated by electronic integration of left ventricular pressure (P) and segmental length (L) over the entire cardiac cycle 13 : SW d P L = ∫ × SW and EDL were fitted using linear regression to the equation:
where Msw:slope of the preload recruitable stroke work (PRSW) and Lw:x-intercept. The concept of preload recruitable stroke work is based on a linear relationship between myocardial work and myocardial preload, as assessed by the end-diastolic dimension. Myocardial work or segmental stroke work is calculated as the area of the pressure-length loop, that is integration of left ventricular pressure (P) and segmental length over the entire cardiac cycle. By occluding the inferior vena cava (caval occlusion) a series of pressure-length loops can be obtained whose areas can be plotted against their end-diastolic lengths. This is a linear relationship and gives the slope of the preload recruitable stroke work (Msw). Table 1 Effects of isoflurane (I) and isoflurane with nicorandil (I;N) on systemic haemodynamics (mean (SEM)). HR:Heart rate; SAP:systolic arterial pressure; LVEDP:left ventricular end-diastolic pressure; PAP:pulmonary arterial pressure; CVP:central venous pressure; CO:cardiac output; COF:coronary flow; Tau:time constant of relaxation; Iso. effect:ANOVA within-subject analysis for the isoflurane factor; Nic. effect:ANOVA within-subject analysis for the nicorandil factor Isoflurane concentration (%) This assessment of ventricular contractility is independent of heart rate and loading status. It represents a linearization of the Frank-Starling relation. In our studies the linear correlation coefficient was greater than 0.90 in all measurements. Figure 1 shows an example of the series of pressure-length loops obtained during caval occlusion and the linear relationship obtained between segmental stroke work and end-diastolic length.
Msw and %SS were expressed as Msw norm and %SS norm (isoflurane alone values were normalized to those obtained at the first measurement. Isoflurane and nicorandil measurements were normalized to those obtained at 1.05% isoflurane just before infusion of nicorandil).
STATISTICAL ANALYSIS
All values are expressed as mean (SEM). Data were analysed using SPSS (SPSS for Windows, release 7, SPSS Inc., Chicago, IL, USA). Two different factors (isoflurane concentration (four levels), drug (two levels)) were analysed using two-way ANOVA for repeated measurements. Changes within each factor were considered statistically significant when P:0.05. A paired t test was used to compare the first measurement obtained at 1.05% isoflurane and measurements obtained at the same isoflurane concentration before infusion of nicorandil. This was done to check that variables had returned to baseline values after the initial increases in isoflurane concentration.
Results
One dog was excluded from the study because of surgical problems. Therefore, all data are from the remaining nine dogs. Table 1 shows the dose-response to isoflurane, before and after infusion of nicorandil, on systemic haemodynamic variables. There were no significant differences between measurements at 1.05% isoflurane and the return measurement at 1.05% isoflurane before infusion of nicorandil for all variables. Increasing the concentration of isoflurane decreased heart rate. Addition of nicorandil shifted the heart rate dose-response to isoflurane upwards, with higher heart rate values at all concentrations of isoflurane. Systolic arterial pressure ( fig. 2 ) decreased with increasing isoflurane concentration (121 (4) to 87 (2) mm Hg at 1.05% and 2.1% isoflurane, respectively) with concurrent administration of nicorandil shifting the systolic arterial pressure doseresponse to isoflurane downwards (110 (4) to 70 (3) mm Hg at 1.05% and 2.1% isoflurane, respectively). Central venous pressure increased with isoflurane concentration; addition of nicorandil had no effect. Global indices of ventricular function (;dP/dtmax and 9dP/dtmax) decreased with increasing isoflurane Figure 2 Dose-response of systolic arterial pressure (SAP) to increasing concentraions of isoflurane after administration of isoflurane alone or combined administration of isoflurane and nicorandil. *P:0.05, ANOVA within-subject analysis for the isoflurane factor; †P:0.05, ANOVA within-subject analysis for the nicorandil factor. Figure 3 Dose-response of Msw norm to increasing concentraion of isofluranes after administration of isoflurane alone or combined administration of isoflurane and nicorandil. *P:0.05, ANOVA witin-subject analysis for the isoflurane factor. Table 2 Effects of isoflurane (I) and isoflurane with nicorandil (I;N) on regional function (mean (SEM)). EDL:End-diastolic length; %SS norm :systolic shortening normalized to the values obtained at 1.05% isoflurane and at 1.05% isoflurane just before infusion of nicorandil. Msw norm :slope of preload recruitable stroke work normalized to the values obtained at 1.05% isoflurane and at 1.05% isoflurane just before infusion of nicorandil. Iso. effect:ANOVA within-subject analysis for the isoflurane factor; Nic. effect:ANOVA within-subject analysis for the nicorandil factor Isoflurane concentration (%) ANOVA (6) 99 (6) 86 (7) 76 (5) Msw norm I 100 81 (7) 71 (9) 60 (11) :0.001 ns I+N 120 (11) 92 (11) 86 (7) 76 (12) concentration; this was accentuated in the presence of nicorandil. Increasing the concentration of isoflurane decreased cardiac output. Addition of nicorandil had no effect. There was no change in coronary flow at any concentration of isoflurane, however, coronary flow increased in the presence of nicorandil. The time constant of isovolumic relaxation (tau) remained unchanged with increasing isoflurane concentration but decreased with addition of nicorandil.
Regional function data are summarized in 3 ) were depressed in a dose-dependent manner with increasing isoflurane concentration. This was not altered by nicorandil. %SS decreased by approximately 30% between the lowest and highest concentrations of isoflurane; nicorandil had no significant effect. Msw norm decreased from 100 to 60 (11)%, at 1.05% and 2.1% isoflurane, respectively; nicorandil had no significant effect. Initial plasma concentration of nicorandil 30 min after bolus administration of 100 g kg 91 and at the beginning of infusion of 25 g kg 91 min 91 was 0.50 (0.04) mg litre
91
. Plasma concentrations increased during the study to reach 0.99 (0.04) mg litre 91 at the end of the experiment (table 3) .
Discussion
Nicorandil, a novel K ATP channel opener, has been shown to have profound effects on the cardiovascular system, producing alterations in preload and afterload by its vasodilatory effects on the venous and arterial circulations.
14 Clinical studies have shown that nicorandil significantly reduced left ventricular end-diastolic diameter and pressure by reduction in left ventricular filling. 15 16 Nicorandil also caused marked reductions in afterload, as shown by significant decreases in systolic pressure, associated with dilatation of peripheral large arteries resulting in decreased diastolic arterial pressure. 17 These actions of nicorandil can be attributed to its nitrate moiety and a selective increase in K
; conductance by opening ATP-sensitive potassium (K ATP ) channels. This shortens the action potential, reducing transsarcolemmal Ca 2+ influx. 18 The effects of isoflurane on the cardiovascular system have been well documented, both clinically and experimentally. Haemodynamically, it has been well established that isoflurane produces dose-related decreases in arterial pressure (systolic, diastolic and mean), stroke volume and global indices of contractility, such as ;dP/dt. 5 19-21 Regional indices of contractility such as systolic shortening and preload recruitable stroke work are also decreased in a dosedependent manner. 5 22 23 The negative inotropic and vasodilatory actions of volatile anaesthetics such as isoflurane can be attributed to alterations in voltagedependent slow calcium (Ca 2; ) channel activity in the sarcolemmal membrane. 24 It has been shown that isoflurane causes depression of Ca 2; influx during membrane excitation and a reduction in sarcoplasmic reticulum Ca 2; release, resulting ultimately in less Ca 2; available for the contractile proteins. 25 However, recent studies 8 9 have shown that isofluraneinduced vasodilatation was antagonized by glibenclamide, an inhibitor of the K ATP channel, suggesting that the vasodilatory action of isoflurane is mediated partly by K ATP channels.
With such profound individual effects of nicorandil and isoflurane on systemic haemodynamics and cardiac function, the question must be raised as to whether there may be an additive action after combined administration.
Our results showed that increasing isoflurane concentrations, ranging from 1.05% to 2.1%, produced expected "typical" dose-responses: a decrease in heart rate, systolic pressure and cardiac output. Systolic contractility, as assessed by preload recruitable stroke work (PRSW), a load-independent index, 13 and systolic shortening, decreased in a dosedependent manner. These results have been confirmed in similar experimental models. 22 23 Increases in isoflurane concentration produced no change in coronary flow. This is expected as isoflurane causes dose-related coronary vasodilatation, thus allowing flow to be maintained while diastolic arterial pressure is decreasing. Pagel and colleagues 21 found that isoflurane (1.25 MAC) increased coronary flow and reduced end-diastolic pressure and systemic vascular resistance when conscious and anaesthetized dogs were compared. Increasing the isoflurane concentration to 1.75 MAC did not change these variables further.
In the presence of nicorandil, we found that there were downward shifts in end-diastolic pressure (ns) and end-diastolic length dose-responses to isoflurane. This would suggest that a vasodilatory effect of nicorandil with isoflurane occurs in the venous circulation, leading to a reduction in preload. The heart rate dose-response to isoflurane shifted upwards in the presence of nicorandil, probably as a result of a reflex reaction to the decrease in systolic pressure. Although heart rate increased, cardiac output did not increase and therefore stroke volume must have decreased, possibly as a result of a postulated increase in venous capacitance. We showed also a slight downward shift in the systolic pressure dose-response to isoflurane in the presence of nicorandil. By studying nicorandil in conscious dogs, Humphrey and Schwende 26 showed that after 2 h of i.v. infusion, a nicorandil plasma concentration of 0.8 mg litre
91 correlated with a reduction in mean arterial , respectively. Nicorandil is known to produce an increase in coronary flow via its vasodilatory action. 17 27 In our study we found an upward shift in the coronary flow dose-response to isoflurane in the presence of nicorandil, confirming the coronary vasodilatory properties of this agent. As the coronary vasodilatation produced by isoflurane was enhanced by nicorandil, this suggests that either there is an additive effect on K ATP channels or the two drugs are causing vasodilatation via different mechanisms. In patients with steal prone distribution of coronary lesions, the additive coronary dilator effect of both drugs may be deleterious by inducing coronary steal. Indeed coronary steal has been described with isoflurane 28 and with pinacidil, another K ATP channel opener. 29 The time constant of relaxation (tau) doseresponse to isoflurane showed a downward shift in the presence of nicorandil. This index of isovolumic relaxation must be interpreted carefully; it is affected by changes in heart rate and loading conditions. 30 31 Infusion of nicorandil shifted the dP/dtmax doseresponse to isoflurane. However, this global index of contractility is known to be affected by changes in loading status. 32 As mentioned previously, there appeared to be a decrease in preload with nicorandil; this could account for the decrease in dP/dtmax. Load-independent indices such as Msw norm 13 did not change with addition of nicorandil. Other studies concur with the observation that nicorandil has no effect on contractility. 2 In patients with coronary artery disease, nicorandil 20 mg orally decreased mean arterial pressure and peripheral arterial resistance without changing left ventricular contractility. 33 However, in another study, 34 ventricular function assessed angiographically and by echocardiography improved after pacing-induced myocardial ischaemia. This improvement was related to the coronary vasodilator properties of nicorandil. Our study carried out in dogs without coronary stenosis showed no change in ventricular function (assessed by systolic shortening and by the load-independent index, PRSW) when continuous perfusion of nicorandil was added to isoflurane anaesthesia.
Plasma concentrations of nicorandil tended to increase during the experiment. The dose of nicorandil (100 g kg 91 bolus, 25 g kg 91 min 91 continuous infusion) used in this study has been used in similar animal models. 2 Nicorandil concentrations measured in our study were close to therapeutic blood concentrations measured clinically. In patients with congestive heart failure, a single dose of nicorandil 40 mg orally resulted in a concentration of 0.45 mg litre
91
. 35 In healthy subjects, therapeutic blood concentrations were in a similar range: a single dose of nicorandil 40 mg orally produced a maximum concentration of 0.49 (0.26) mg litre 91 . 36 Our study was performed in an acute, anaesthetized, open chest preparation. Therefore, the haemodynamic effects of the drugs may have been affected by the acute surgical intervention. Only nine animals were included in the study and the within-animal comparison was performed without a crossover design because of the prolonged half-life of nicorandil and the possibility of carry-over effects. The duration of the study was long, and we cannot exclude the possible effects of deterioration of the preparation. However, previous studies in this department have shown that this model remains stable for at least 4 h after the start of data collection.
In summary, concurrent administration of isoflurane and nicorandil caused additional vaso/ venodilatory effects in a canine preparation compared with isoflurane alone. However, ventricular function was unaffected by combined administration of both drugs. Therefore, the association of isoflurane and nicorandil appears to be safe. However, we would exercise caution when extrapolating results in acutely instrumented dogs to the clinical setting.
